ARxIUM and Prinses Máxima Centrum top 1 million sterile doses with RIVA

ARxIUM said Prinses Máxima Centrum has compounded more than one million patient-specific sterile doses using its RIVA IV automation platform. The milestone underscores how pharmacy automation is helping the European pediatric cancer center manage complex oncology preparations with greater consistency and efficiency.

Why it matters: - The milestone shows how pharmacy automation can support high-volume, patient-specific sterile compounding in pediatric oncology. - Prinses Máxima Centrum’s workflow depends on precise preparation for children with cancer, where treatment regimens often require individualized medications. - ARxIUM frames the result as evidence that automation can help pharmacies improve consistency, reliability and operational capacity as medication complexity rises.

What happened: - ARxIUM announced on September 21, 2026, that Prinses Máxima Centrum surpassed one million patient-specific sterile doses compounded with its RIVA IV automation platform. - Prinses Máxima Centrum is the largest pediatric oncology center in Europe. - The milestone reflects years of collaboration between the two organizations focused on medication quality and specialized pediatric cancer care. - The Princess Máxima Center, in Utrecht, Netherlands, treats all children with cancer in the Netherlands.

The details: - Prinses Máxima Centrum opened its dedicated preparation pharmacy in 2018. - Two RIVA systems have supported sterile medication preparation at the center since then. - The platform has been used for both routine sterile preparations and high-risk oncology medications. - ARxIUM said RIVA helps reduce manual steps and standardize the compounding workflow. - The pharmacy team uses the system to manage high volumes of patient-specific preparations while maintaining process control and accuracy. - ARxIUM is a pharmacy automation and workflow company with products spanning IV compounding, dispensing and packaging, high-volume vial filling, centralized service center solutions and enterprise software. - Prinses Máxima Centrum describes itself as a research hospital with more than 450 researchers and 900 healthcare professionals.

Between the lines: - The milestone suggests automation is becoming more embedded in specialized hospital pharmacy operations, not just used for isolated efficiency gains. - For pediatric oncology centers, standardized compounding can matter as much as speed because dosing often must be tailored to individual patients. - The announcement also positions automation as a response to workforce pressure and rising expectations for quality in healthcare delivery. - Nhat H. Ngo, CEO of ARxIUM, said the achievement illustrates how automation can help pharmacy teams create dependable workflows and build future capacity. - Dr. Lidwien Hanff, director of pharmacy at Prinses Máxima Centrum, said the partnership supports complex treatment schedules while helping the pharmacy team work more efficiently.

What's next: - ARxIUM said the milestone points to long-term value from continued use of automation in specialized compounding environments. - Prinses Máxima Centrum is expected to keep using RIVA to support pediatric oncology pharmacy operations. - ARxIUM’s broader push remains focused on helping hospitals standardize workflows, scale operations and improve medication safety.

The bottom line: - The one-million-dose mark is a concrete sign that automation has moved from promise to routine infrastructure in a leading pediatric cancer pharmacy.